The role of CDK4/6 inhibitors in early breast cancer

Breast. 2021 May 25;58:160-169. doi: 10.1016/j.breast.2021.05.008. Online ahead of print.ABSTRACTThe use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.PMID:34087775 | DOI:10.1016/j.breast.2021.05.008
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research